Nanotechnology and COVID-19: quo vadis?
Source abstract
Abstract
The pandemic COVID-19 has worried everyone due to the high mortality rate and the high number of people hospitalized with severe acute respiratory syndrome caused by SARS-CoV-2. Given the seriousness of this disease, several companies and research institutions have sought alternative treatment and/or prevention methods for COVID-19. Due to its versatility, nanotechnology has allowed the development of protective equipment and vaccines to prevent the disease and reduce the number of severe COVID-19 cases. Thus, this article combined the main works and products developed in a nanotechnological field for COVID-19. We performed a literature search using the keywords "COVID-19," "SARS-CoV-2," "nanoparticles," "nanotechnology," and "liposomes" in the SciELO, Scifinder, PubMed, Sciencedirect, ClinicalTrials, and Nanotechnology Products databases Database. The data survey indicated 48 articles, 62 products, and 32 patents. The use of nanotechnology against COVID-19 has brought benefits in several parameters of this disease, helping develop rapid diagnostic tests that release the result in 10 min, as well as developing vaccines containing genetic material from SARS-CoV-2 (DNA, mRNA, and protein subunits). Nanotechnology is an exceptional ally against COVID-19, contributing to the most diverse areas, helping both prevent, diagnose, and treat COVID-19.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 detection and testing · SARS-CoV-2 and COVID-19 Research · COVID-19 diagnosis using AI
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (80)
Show source-provided references
1. Almeida DS, Martins LD, Muniz EC, Rudke AP, Squizzato R, Beal A et al (2020) Biodegradable CA/CPB electrospun nanofibers for efficient retention of airborne nanoparticles. Process Saf Environ Prot 144:177–185. https://doi.org/10.1016/j.psep.2020.07.02410.1016/j.psep.2020.07.024 ↗
2. Anselmo AC, Mitragotri S (2019) Nanoparticles in the clinic: an update. Bioengineering & Translational Medicine 4(3):e10143. https://doi.org/10.1002/btm2.1014310.1002/btm2.10143 ↗
3. Bhat EA, Khan J, Sajjad N, Ali A, Aldakeel FM, Mateen A et al (2021) SARS-CoV-2: insight in genome structure, pathogenesis and viral receptor binding analysis – an updated review. Int Immunopharmacol 95:107493. https://doi.org/10.1016/j.intimp.2021.10749310.1016/j.intimp.2021.107493 ↗
4. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016) Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 33(10):2373–2387. https://doi.org/10.1007/s11095-016-1958-510.1007/s11095-016-1958-5 ↗
5. Callaway E, Mallapaty S (2021) Novavax offers first evidence that COVID vaccines protect people against variants. Nature. Available in: https://www.nature.com/articles/d41586-021-00268-9. Accessed in: May 12, 2021
6. Caster JM, Patel AN, Zhang T, Wang A (2016) Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 9(1):e1416. https://doi.org/10.1002/wnan.141610.1002/wnan.1416 ↗
7. Cavalcanti IDL, Nogueira MCBL (2020) Pharmaceutical nanotechnology: which products are been designed against COVID-19? J Nanoparticle Res 22(276). https://doi.org/10.1007/s11051-020-05010-610.1007/s11051-020-05010-6 ↗
8. Cavalcanti IDL, Medeiros SMFRS, Macêdo DCS, Cavalcanti IMF, Nogueira MCBL (2020) Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: an alternative to COVID-19. Current Drug Delivery 17 https://doi.org/10.2174/156720181766620082711044510.2174/1567201817666200827110445 ↗
9. Chan WCW (2020) Nano research for COVID-19. ACS Nano. https://doi.org/10.1021/acsnano.0c0254010.1021/acsnano.0c02540 ↗
10. Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO (2020) Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano 17:7760–7782. https://doi.org/10.1021/acsnano.0c0400610.1021/acsnano.0c04006 ↗
11. Cheng R, Ou S (2019) Nanocomposite-based graphene for nanosensor applications. Intechopen. London, United Kingdom10.5772/intechopen.85136 ↗
12. Choudhary J, Dheeman S, Sharma V, Katiyar P, Karn SK, Sarangi MK et al (2021) Insights of severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic: a current review. Biological Procedures Online 23(5). https://doi.org/10.1186/s12575-020-00141-510.1186/s12575-020-00141-5 ↗
13. Dai L, Gao GF (2021) Viral targets for vaccines against COVID-19. Nat Rev Immunol 21:73–82. https://doi.org/10.1038/s41577-020-00480-010.1038/s41577-020-00480-0 ↗
14. Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM et al (2021) Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184(11):2939–2954. https://doi.org/10.1016/j.cell.2021.03.05510.1016/j.cell.2021.03.055 ↗
15. Douafer H, Andrieu V, Brunel JM (2020) Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases. J Control Release 325:276–292. https://doi.org/10.1016/j.jconrel.2020.07.00210.1016/j.jconrel.2020.07.002 ↗
16. Draz MS, Shafiee H (2018) Applications of gold nanoparticles in virus detection. Theranostics 8(7):1985–2017. https://doi.org/10.7150/thno.2385610.7150/thno.23856 ↗
17. Fan FR, Tian ZQ, Wang ZL (2012) Flexible triboelectric generator. Nano Energy 1(2):328–334. https://doi.org/10.1016/j.nanoen.2012.01.00410.1016/j.nanoen.2012.01.004 ↗
18. Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR (2019) Nanopharmaceutical and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (london) 14(1):93–126. https://doi.org/10.2217/nnm-2018-012010.2217/nnm-2018-0120 ↗
19. FDA – U.S. Food & Drug Administration (2020) Search for FDA guidance documents [Internet]. FDA. Available from: http://www.fda.gov/regulatory-information/search-fda-guidance-documents. Accessed in: June 6, 2021.
20. Forni G, Mantovani A (2021) COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28:626–639. https://doi.org/10.1038/s41418-020-00720-910.1038/s41418-020-00720-9 ↗
21. Galdiero M, Galdiero M, Folliero V, Zannella C, Filippis A, Mali A et al (2021) SARS-CoV-2 vaccine development: where are we? Eur Rev Med Pharmacol Sci 25:2752–2784
22. Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Aslund AKO et al (2020) Delivering the power of nanomedicine to patients today. J Control Release 326:164–171. https://doi.org/10.1016/j.jconrel.2020.07.00710.1016/j.jconrel.2020.07.007 ↗
23. Gupta R, Sagar P, Priyadarshi N, Kaul S, Sandhir R, Rishi V, Singhal NK (2020) Nanotechnology-based approaches for the detection of SARS-CoV-2. Frontiers in Nanotechnology 2:589832. https://doi.org/10.3389/fnano.2020.58983210.3389/fnano.2020.589832 ↗
24. Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S (2021) COVID-19 and cancer: from basic mechanisms to vaccine development using nanotechnology. International Immunopharmacology 90 https://doi.org/10.1016/j.intimp.2020.10724710.1016/j.intimp.2020.107247 ↗
25. Hashemi SA, Golab Behbahan NG, Bahrani S, Mousavi SM, Gholami A, Ramakrishna S et al (2021) Ultra-sensitive viral glycoprotein detection NanoSystem toward accurate tracing SARS-CoV-2 in biological/non-biological media. Biosens Bioelectron 171:112731. https://doi.org/10.1016/j.bios.2020.11273110.1016/j.bios.2020.112731 ↗
26. Huang L, Ding L, Zhou J, Chen S, Chen F, Zhao C et al (2021) One-step rapid quantification of SARS-CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and point-of-care device. Biosens Bioelectron 171:112685. https://doi.org/10.1016/j.bios.2020.11268510.1016/j.bios.2020.112685 ↗
27. Kabir ER, Mustafa N, Nausheen N, Sharif Siam MK, Syed EU (2021) Exploring existing drugs: proposing potential compounds in the treatment of COVID-19. Heliyon 7(2):e06284. https://doi.org/10.1016/j.heliyon.2021.e0628410.1016/j.heliyon.2021.e06284 ↗
28. Kanno AI, Barbosa MMF, Moraes L, Leite LCC (2021) SARS-CoV-2 vaccine development and how Brazil is contributing. Genet Mol Biol 44(1):1–15. https://doi.org/10.1590/1678-4685-gmb-2020-032010.1590/1678-4685-gmb-2020-0320 ↗
29. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S et al (2020) Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 383:2320–2332. https://doi.org/10.1056/NEJMoa202692010.1056/NEJMoa2026920 ↗
30. Khurana A, Allawadhi P, Khurana I, Allwadhi S, Weiskirchen R, Banothu AK et al (2021) Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nanotoday 38(101142) https://doi.org/10.1016/j.nantod.2021.10114210.1016/j.nantod.2021.101142 ↗
31. Kostarelos K (2020) Nanoscale nights of COVID-19. Nat Nanotechnol 15(5):343–344. https://doi.org/10.1038/s41565-020-0687-410.1038/s41565-020-0687-4 ↗
32. Kumar AU, Kadiresen K, Gan WC, Ling APK (2021) Current updates and research on plant-based vaccines for coronavirus disease 2019. Clinical and Experimental Vaccine Research 10(1):13–23. https://doi.org/10.7774/cevr.2021.10.1.1310.7774/cevr.2021.10.1.13 ↗
33. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO (2021) SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines 6(28). https://doi.org/10.1038/s41541-021-00292-w.10.1038/s41541-021-00292-w ↗
34. Lee J, Kim J (2020) Material properties influencing the charge decay of electret filters and their impact on filtration performance. Polymers 12(3):721. https://doi.org/10.3390/polym1203072110.3390/polym12030721 ↗
35. Leung WWF, Sun Q (2020) Electrostatic charged nanofiber filter for filtering airborne novel coronavirus (COVID-19) and nano-aerosols. Separation and Purification Technology 116886 https://doi.org/10.1016/j.seppur.2020.11688610.1016/j.seppur.2020.116886 ↗
36. Liu D, Ju C, Han C, Shi R, Chen X, Duan D et al (2020a) Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen. Biosens Bioelectron 173:112817. https://doi.org/10.1016/j.bios.2020.11281710.1016/j.bios.2020.112817 ↗
37. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ et al (2020b) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 6(3):315–331. https://doi.org/10.1021/acscentsci.0c0027210.1021/acscentsci.0c00272 ↗
38. Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet 395(10240):1820. https://doi.org/10.1016/S0140-6736(20)31180-610.1016/S0140-6736(20)31180-6 ↗
39. Mehta M, Prasher P, Sharma M, Shastri MD, Khurana N, Vyas M et al (2020) Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): a hypothesis. Medical Hypotheses 144. https://doi.org/10.1016/j.mehy.2020.110254.10.1016/j.mehy.2020.110254 ↗
40. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E (2020) A novel coronavirus emerging in China — key questions for impact assessment. N Engl J Med 382(8):692–694. https://doi.org/10.1056/NEJMp200092910.1056/NEJMp2000929 ↗
41. NanoBio® Protect Nasal Antiseptic Solution (2020) Available in: https://www.nanobioprotect.com. Accessed in: June 6, 2021
42. Nanomatrix materials (2021) Available in: https://www.nmmaterials.com. Accessed in: June 6, 2021
43. Nanotechnology Products Database (2020.) COVID-19 Available in: https://product.statnano.com/. Accessed in: June 6, 2021
44. Nel AE, Miller JF (2021) Nano-enabled COVID-19 vaccines: meeting the challenges of durable antibody plus cellular immunity and immune escape. ACS Nano. https://doi.org/10.1021/acsnano.1c0184510.1021/acsnano.1c01845 ↗
45. Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ et al (2021) Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. Journal of Nanobiotechnology 19(59) https://doi.org/10.1186/s12951-021-00806-710.1186/s12951-021-00806-7 ↗
46. Novochizol (2020) Aerosol formulation of COVID-19. Available in: https://www.novochizol.ch/. Accessed in: June 6, 2021
47. Palmieri V, De Maio F, De Spirito M, Papi M (2021) Face masks and nanotechnology: keep the blue side up. Nano Today 37:101077. https://doi.org/10.1016/j.nantod.2021.10107710.1016/j.nantod.2021.101077 ↗
48. Patented anti-microbial NanoDiamonds (ND) mask. 2020. Available in: https://www.master-dynamic.com. Accessed in: June 6, 2021
49. Pati R, Shevtsov M, Sonawane A (2018) Nanoparticle vaccines against infectious diseases. Frontiers in Immunology 9(2224). https://doi.org/10.3389/fimmu.2018.02224.10.3389/fimmu.2018.02224 ↗
50. Pindiprolu SKSS, Kumar CSP, Kumar Golla VS, P. L, K. SC, S.K. EB, et al (2020) Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent. Medical Hypotheses 143:109858 https://doi.org/10.1016/j.mehy.2020.10985810.1016/j.mehy.2020.109858 ↗
51. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615. https://doi.org/10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
52. Poole CP, Owens FJ (2010) Introduction to nanotechnology. New Delhi: Wiley India
53. Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S et al (2020) A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. BioRxiv. https://doi.org/10.1101/2020.08.28.27251810.1101/2020.08.28.272518 ↗
54. Rao VK (2021) Point of care diagnostic devices for rapid detection of novel coronavirus (SARS-nCoV19) pandemic: a review. Frontiers in Nanotechnology 2:593619. https://doi.org/10.3389/fnano.2020.59361910.3389/fnano.2020.593619 ↗
55. Refaat H, Mady FM, Sarhan HA, Rateb HS, Alaaeldin E (2021) Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19. Int J Pharm 592:120028. https://doi.org/10.1016/j.ijpharm.2020.12002810.1016/j.ijpharm.2020.120028 ↗
56. Reinholz J, Landfester K, Mailänder V (2018) The challenges of oral drug delivery via nanocarriers. Drug Delivery 25(1):1694–1705. https://doi.org/10.1080/10717544.2018.150111910.1080/10717544.2018.1501119 ↗
57. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M et al (2020) COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586:594–599. https://doi.org/10.1038/s41586-020-2814-710.1038/s41586-020-2814-7 ↗
58. Saunders KO, Lee E, Parks R, Martinez DR, Li D, Chen H et al (2021) Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. https://doi.org/10.1038/s41586-021-03594-010.1038/s41586-021-03594-0 ↗
59. Shih H-I, Wu C-J, Tu Y-F, Chi C-Y (2020) Fighting COVID-19: a quick review of diagnoses, therapies, and vaccines. Biomedical Journal 43(4):341–354. https://doi.org/10.1016/j.bj.2020.05.02110.1016/j.bj.2020.05.021 ↗
60. Shin MD, Shukla S, Chung YH, Beiss V, Chan SK, Ortega-Rivera OA et al (2020) COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol 15:646–655. https://doi.org/10.1038/s41565-020-0737-y10.1038/s41565-020-0737-y ↗
61. Simone-Finstrom M, Spivak M (2010) Propolis and bee health: the natural history and significance of resin use by honey bees. Apidologie 41(3):295–311. https://doi.org/10.1051/apido/201001610.1051/apido/2010016 ↗
62. The Lancet Microbe (2021) COVID-19 vaccines: the pandemic will not end overnight. The Lancet Microbe Editorial 2(1):e1. https://doi.org/10.1016/S2666-5247(20)30226-310.1016/S2666-5247(20)30226-3 ↗
63. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC et al (2020) Diagnosing COVID-19: the disease and tools for detection. ACS Nano 14(4). https://doi.org/10.1021/acsnano.0c02624.10.1021/acsnano.0c02624 ↗
64. Uzunian A (2020) Coronavirus SARS-CoV-2 and Covid-19. Jornal Brasileiro De Patologia e Medicina Laboratorial 56:1–4. https://doi.org/10.5935/1676-2444.2020005310.5935/1676-2444.20200053 ↗
65. Valizadeh H, Abdolmohammadi-vahid S, Danshina S, Ziya Gencer M, Ammari A, Sadeghi A et al (2020) Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol 89:107088. https://doi.org/10.1016/j.intimp.2020.10708810.1016/j.intimp.2020.107088 ↗
66. Vasir J, Reddy M, Labhasetwar V (2005) Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 1(1):47–64. https://doi.org/10.2174/157341305295311010.2174/1573413052953110 ↗
67. Walls AC, Fiala B, Schafer A, Wrenn S, Pharm MN, Murphy M et al (2020) Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183(5):1367–1382. https://doi.org/10.1016/j.cell.2020.10.04310.1016/j.cell.2020.10.043 ↗
68. Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A et al (2020a) RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. N Engl J Med. https://doi.org/10.1056/NEJMoa202790610.1056/NEJMoa2027906 ↗
69. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A et al (2020b) Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med 383(25):2439–2450. https://doi.org/10.1056/NEJMoa202790610.1056/NEJMoa2027906 ↗
70. Wang X, Sun W, Yang W, Gao S, Sun C, Li Q (2019) Mesoporous silica-protected silver nanoparticle disinfectant with controlled Ag+ ion release, efficient magnetic separation, and effective antibacterial activity. Nanoscale Advances 1(2):840–848. https://doi.org/10.1039/C8NA00275D10.1039/C8NA00275D ↗
71. WHO (2020b) World Health Organization. Coronavirus disease 2019 (cOVID-19) situation report - 84. Available in: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Access in: July 7, 2021.
72. Wise J (2021) Covid-19: is vaccination roll out reducing cases and deaths in the UK? The BMJ 372(506). https://doi.org/10.1136/bmj.n50610.1136/bmj.n506 ↗
73. Wu C, Wang AC, Ding W, Guo H, Wang ZL (2018) Triboelectric nanogenerator: a foundation of the energy for the new era. Adv Energy Mater 9(1):1802906. https://doi.org/10.1002/aenm.20180290610.1002/aenm.201802906 ↗
74. Yan ZP, Yang M, Lai CL (2021) COVID-19 vaccines: a review of the safety and efficacy of current clinical trials. Pharmaceuticals 14(406). https://doi.org/10.3390/ph14050406.10.3390/ph14050406 ↗
75. Yang D (2021) Application of nanotechnology in the COVID-19 pandemic. Int J Nanomed 16:623–649. https://doi.org/10.2147/IJN.S29638310.2147/IJN.S296383 ↗
76. Zhang Y, Zhang H, Wang X, Wang J, Zhang X, Zhang Q (2012) The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 33(2):679–691. https://doi.org/10.1016/j.biomaterials.2011.09.07210.1016/j.biomaterials.2011.09.072 ↗
77. Zhang Q, Honko A, Zhou J, Gong H, Downs SN, Vasquez JH et al (2020a) Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett 20(7):5570–5574. https://doi.org/10.1021/acs.nanolett.0c0227810.1021/acs.nanolett.0c02278 ↗
78. Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G et al (2020b) A thermostable mRNA vaccine against COVID-19. Cell 182(5):1271–1283. https://doi.org/10.1016/j.cell.2020.07.02410.1016/j.cell.2020.07.024 ↗
79. Zhang R, Hristovski D, Schutte D, Kastrin A, Fiszman M, Kilicoglu H (2021a) Drug repurposing for COVID-19 via knowledge graph completion. J Biomed Inform 115:103696. https://doi.org/10.1016/j.jbi.2021.10369610.1016/j.jbi.2021.103696 ↗
80. Zhang R, Xu Q, Bai S, Hai J, Cheng L, Xu G et al (2021b) Enhancing the filtration efficiency and wearing time of disposable surgical masks using TENG technology. Nano Energy 79:105434. https://doi.org/10.1016/j.nanoen.2020.10543410.1016/j.nanoen.2020.105434 ↗